165 related articles for article (PubMed ID: 17631559)
1. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG.
Dimitrakopoulou-Strauss A; Hohenberger P; Haberkorn U; Mäcke HR; Eisenhut M; Strauss LG
J Nucl Med; 2007 Aug; 48(8):1245-50. PubMed ID: 17631559
[TBL] [Abstract][Full Text] [Related]
2. Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line.
Cheng C; Pan L; Dimitrakopoulou-Strauss A; Schäfer M; Wängler C; Wängler B; Haberkorn U; Strauss LG
EJNMMI Res; 2011 Dec; 1():34. PubMed ID: 22214362
[TBL] [Abstract][Full Text] [Related]
3. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
Schuhmacher J; Zhang H; Doll J; Mäcke HR; Matys R; Hauser H; Henze M; Haberkorn U; Eisenhut M
J Nucl Med; 2005 Apr; 46(4):691-9. PubMed ID: 15809493
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
5. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography (PET) and macromolecular delivery in vivo.
Strauss LG; Dimitrakopoulou-Strauss A
Methods Mol Biol; 2009; 480():187-98. PubMed ID: 19085122
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic studies of ⁶⁸Ga-labeled Bombesin (⁶⁸Ga-BZH₃) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results.
Dimitrakopoulou-Strauss A; Seiz M; Tuettenberg J; Schmieder K; Eisenhut M; Haberkorn U; Strauss LG
Clin Nucl Med; 2011 Feb; 36(2):101-8. PubMed ID: 21220970
[TBL] [Abstract][Full Text] [Related]
9. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
10. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid.
Lococo F; Perotti G; Cardillo G; De Waure C; Filice A; Graziano P; Rossi G; Sgarbi G; Stefanelli A; Giordano A; Granone P; Rindi G; Versari A; Rufini V
Clin Nucl Med; 2015 Mar; 40(3):e183-9. PubMed ID: 25608152
[TBL] [Abstract][Full Text] [Related]
11. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
12. Dynamic PET with FDG in patients with unresectable aggressive fibromatosis: regression-based parametric images and correlation to the FDG kinetics based on a 2-tissue compartment model.
Dimitrakopoulou-Strauss A; Hohenberger P; Pan L; Kasper B; Roumia S; Strauss LG
Clin Nucl Med; 2012 Oct; 37(10):943-8. PubMed ID: 22899201
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.
Morgat C; Schollhammer R; Macgrogan G; Barthe N; Vélasco V; Vimont D; Cazeau AL; Fernandez P; Hindié E
PLoS One; 2019; 14(1):e0210905. PubMed ID: 30645633
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus.
Mäkinen TJ; Lankinen P; Pöyhönen T; Jalava J; Aro HT; Roivainen A
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1259-68. PubMed ID: 16007423
[TBL] [Abstract][Full Text] [Related]
15. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis.
Okazumi S; Dimitrakopoulou-Strauss A; Schwarzbach MH; Strauss LG
Hell J Nucl Med; 2009; 12(3):223-8. PubMed ID: 19936332
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids.
Jindal T; Kumar A; Venkitaraman B; Meena M; Kumar R; Malhotra A; Dutta R
Cancer Imaging; 2011 Jun; 11(1):70-5. PubMed ID: 21697027
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
Spence AM; Muzi M; Mankoff DA; O'Sullivan SF; Link JM; Lewellen TK; Lewellen B; Pham P; Minoshima S; Swanson K; Krohn KA
J Nucl Med; 2004 Oct; 45(10):1653-9. PubMed ID: 15471829
[TBL] [Abstract][Full Text] [Related]
19. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
Henze M; Dimitrakopoulou-Strauss A; Milker-Zabel S; Schuhmacher J; Strauss LG; Doll J; Mäcke HR; Eisenhut M; Debus J; Haberkorn U
J Nucl Med; 2005 May; 46(5):763-9. PubMed ID: 15872348
[TBL] [Abstract][Full Text] [Related]
20. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
